386 related articles for article (PubMed ID: 34153064)
1. Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia.
Kövy P; Őrfi Z; Bors A; Kozma A; Gopcsa L; Dolgos J; Lovas N; Harasztdombi J; Lakatos V; Király Á; Mikala G; Vályi-Nagy I; Reményi P; Andrikovics H
PLoS One; 2021; 16(6):e0253386. PubMed ID: 34153064
[TBL] [Abstract][Full Text] [Related]
2. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
3. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
Jia ZX; Zhou M; Chao HY; Lu XZ; Zhang R; Cen L; Xiao R; Jiang NK
Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):397-401. PubMed ID: 22781800
[TBL] [Abstract][Full Text] [Related]
6. IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?
Petrova L; Vrbacky F; Lanska M; Zavrelova A; Zak P; Hrochova K
Clin Biochem; 2018 Nov; 61():34-39. PubMed ID: 30176240
[TBL] [Abstract][Full Text] [Related]
7. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Marcucci G; Maharry K; Wu YZ; Radmacher MD; Mrózek K; Margeson D; Holland KB; Whitman SP; Becker H; Schwind S; Metzeler KH; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2010 May; 28(14):2348-55. PubMed ID: 20368543
[TBL] [Abstract][Full Text] [Related]
8. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
Freeman SD; Hills RK; Virgo P; Khan N; Couzens S; Dillon R; Gilkes A; Upton L; Nielsen OJ; Cavenagh JD; Jones G; Khwaja A; Cahalin P; Thomas I; Grimwade D; Burnett AK; Russell NH
J Clin Oncol; 2018 May; 36(15):1486-1497. PubMed ID: 29601212
[TBL] [Abstract][Full Text] [Related]
9. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
[TBL] [Abstract][Full Text] [Related]
10. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
[TBL] [Abstract][Full Text] [Related]
11. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.
Yamaguchi S; Iwanaga E; Tokunaga K; Nanri T; Shimomura T; Suzushima H; Mitsuya H; Asou N
Eur J Haematol; 2014 Jun; 92(6):471-7. PubMed ID: 24443894
[TBL] [Abstract][Full Text] [Related]
12. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
[TBL] [Abstract][Full Text] [Related]
13. The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.
Dunlap JB; Leonard J; Rosenberg M; Cook R; Press R; Fan G; Raess PW; Druker BJ; Traer E
Am J Hematol; 2019 Aug; 94(8):913-920. PubMed ID: 31145495
[TBL] [Abstract][Full Text] [Related]
14. [Mutation of isocitrate dehydrogenase 2 (IDH2) gene in Chinese AML patients and its clinical significance].
Shang Z; Wang D; Xiao M; Wang J; Li TJ; Zhao YC; Li CR; Zhou JF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):607-12. PubMed ID: 23815907
[TBL] [Abstract][Full Text] [Related]
15. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
Lachowiez CA; Reville PK; Kantarjian H; Jabbour E; Borthakur G; Daver N; Issa G; Furudate K; Tanaka T; Pierce S; Tang G; Patel KP; Medeiros J; Abbas HA; Haddad F; Hammond D; Short NJ; Maiti A; Yilmaz M; Sasaki K; Takahashi K; Pemmaraju N; Konopleva M; Garcia-Manero G; Ravandi F; Kadia TM; Loghavi S; DiNardo CD
Am J Hematol; 2022 Nov; 97(11):1443-1452. PubMed ID: 36054614
[TBL] [Abstract][Full Text] [Related]
16. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
[TBL] [Abstract][Full Text] [Related]
17. IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia and associated with NPM1 mutations and FAB-M2 subtype.
Chao HY; Jia ZX; Chen T; Lu XZ; Cen L; Xiao R; Jiang NK; Ying JH; Zhou M; Zhang R
Int J Lab Hematol; 2012 Oct; 34(5):502-9. PubMed ID: 22494415
[TBL] [Abstract][Full Text] [Related]
18. Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia.
Al Hamed R; Labopin M; Daguindau E; Niittyvuopio R; Huynh A; Socié G; Srour M; Henri Bourhis J; Kröger N; Tholouli E; Choi G; Poiré X; Martin H; Rubio MT; Jindra P; Blaise D; Beelen D; Labussière-Wallet H; Nagler A; Bazarbachi A; Mohty M
Cancer Med; 2022 Feb; 11(4):1068-1080. PubMed ID: 35048553
[TBL] [Abstract][Full Text] [Related]
19. A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome.
Mason EF; Kuo FC; Hasserjian RP; Seegmiller AC; Pozdnyakova O
Am J Hematol; 2018 Aug; 93(4):504-510. PubMed ID: 29274134
[TBL] [Abstract][Full Text] [Related]
20. Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia.
Koszarska M; Bors A; Feczko A; Meggyesi N; Batai A; Csomor J; Adam E; Kozma A; Orban TI; Lovas N; Sipos A; Karaszi E; Dolgos J; Fekete S; Reichardt J; Lehoczky E; Masszi T; Tordai A; Andrikovics H
Leuk Lymphoma; 2013 May; 54(5):1028-35. PubMed ID: 23039322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
